{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:51:48Z","timestamp":1784235108262,"version":"3.55.0"},"reference-count":209,"publisher":"Elsevier","isbn-type":[{"value":"9780443293207","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["5\/4\\u20135\/3\/13\/Neuro\/2022-NCD-I"],"award-info":[{"award-number":["5\/4\\u20135\/3\/13\/Neuro\/2022-NCD-I"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","award":["30\\u2013564\/2021"],"award-info":[{"award-number":["30\\u2013564\/2021"]}],"id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.pmbts.2024.08.006","type":"book-chapter","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T11:06:47Z","timestamp":1729076807000},"page":"169-207","source":"Crossref","is-referenced-by-count":3,"title":["The Huntington\u2019s disease drug pipeline: a review of small molecules and their therapeutic targets"],"prefix":"10.1016","author":[{"given":"Sameera","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nargis","family":"Bano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir N.","family":"Uversky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9873-7806","authenticated-orcid":false,"given":"Shakir","family":"Ahamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4098-8810","authenticated-orcid":false,"given":"Shahnawaz Ali","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1469-1809.2006.00335.x","article-title":"The relationship between CAG repeat length and age of onset differs for Huntington\u2019s disease patients with juvenile onset or adult onset","volume":"71","author":"Andresen","year":"2007","journal-title":"Ann Hum Genet."},{"issue":"11","key":"10.1016\/bs.pmbts.2024.08.006_bib2","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.1073\/pnas.1922264117","article-title":"Abrogation of prenucleation, transient oligomerization of the huntingtin exon 1 protein by human profilin I","volume":"117","author":"Ceccon","year":"2020","journal-title":"Proc Natl Acad Sci."},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.006_bib3","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The biology of Huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41580-020-00326-6","article-title":"Biomolecular condensates at the nexus of cellular stress, protein aggregation disease and ageing","volume":"22","author":"Alberti","year":"2021","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"10","key":"10.1016\/bs.pmbts.2024.08.006_bib5","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1021\/acs.accounts.0c00450","article-title":"Exploding the repeat length paradigm while exploring amyloid toxicity in Huntington\u2019s disease","volume":"53","author":"Wetzel","year":"2020","journal-title":"ACC Chem Res."},{"issue":"16","key":"10.1016\/bs.pmbts.2024.08.006_bib6","doi-asserted-by":"crossref","first-page":"10855","DOI":"10.1074\/jbc.M804813200","article-title":"Mutant Huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells","volume":"284","author":"Ratovitski","year":"2009","journal-title":"J Biol Chem."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib7","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/s41598-017-01510-z","article-title":"The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington\u2019s disease patients","volume":"7","author":"Neueder","year":"2017","journal-title":"Sci Rep."},{"issue":"4","key":"10.1016\/bs.pmbts.2024.08.006_bib8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/hmg\/ddu504","article-title":"Comparative study of naturally occurring Huntingtin fragments in drosophila points to exon 1 as the most pathogenic species in Huntington\u2019s disease","volume":"24","author":"Barbaro","year":"2015","journal-title":"Hum Mol Genet."},{"issue":"12","key":"10.1016\/bs.pmbts.2024.08.006_bib9","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1021\/cb500335w","article-title":"Super-resolution fluorescence of Huntingtin reveals growth of globular species into short fibers and coexistence of distinct aggregates","volume":"9","author":"Duim","year":"2014","journal-title":"ACS Chem Biol."},{"issue":"8","key":"10.1016\/bs.pmbts.2024.08.006_bib10","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1073\/pnas.96.8.4604","article-title":"Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington\u2019s disease pathology","volume":"96","author":"Scherzinger","year":"1999","journal-title":"Proc Natl Acad Sci."},{"issue":"12","key":"10.1016\/bs.pmbts.2024.08.006_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050750","article-title":"Analysis of proteolytic processes and enzymatic activities in the generation of Huntingtin N-terminal fragments in an HEK293 cell model","volume":"7","author":"Tebbenkamp","year":"2012","journal-title":"PLoS One."},{"issue":"31","key":"10.1016\/bs.pmbts.2024.08.006_bib12","doi-asserted-by":"crossref","first-page":"10541","DOI":"10.1523\/JNEUROSCI.0146-10.2010","article-title":"Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into Huntington\u2019s disease molecular pathogenesis","volume":"30","author":"Miller","year":"2010","journal-title":"J Neurosci."},{"issue":"17","key":"10.1016\/bs.pmbts.2024.08.006_bib13","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.15252\/embj.201490808","article-title":"Huntingtin proteolysis releases Non\u2010polyQ fragments that cause toxicity through dynamin 1 dysregulation","volume":"34","author":"El\u2010Daher","year":"2015","journal-title":"EMBO J."},{"issue":"9","key":"10.1016\/bs.pmbts.2024.08.006_bib14","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.str.2020.06.008","article-title":"The polyglutamine expansion at the N-terminal of huntingtin protein modulates the dynamic configuration and phosphorylation of the C-terminal heat domain","volume":"28","author":"Jung","year":"2020","journal-title":"Structure."},{"issue":"Database issue","key":"10.1016\/bs.pmbts.2024.08.006_bib15","first-page":"D508","article-title":"D2P2: database of disordered protein predictions","volume":"41","author":"Oates","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"12","key":"10.1016\/bs.pmbts.2024.08.006_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4496","article-title":"Rapid prediction and analysis of protein intrinsic disorder","volume":"31","author":"Dayhoff","year":"2022","journal-title":"Protein Sci."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib17","doi-asserted-by":"crossref","first-page":"15462","DOI":"10.1038\/ncomms15462","article-title":"Fibril polymorphism affects immobilized non-amyloid flanking domains of Huntingtin exon1 rather than its polyglutamine core","volume":"8","author":"Lin","year":"2017","journal-title":"Nat Commun."},{"issue":"42","key":"10.1016\/bs.pmbts.2024.08.006_bib18","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1021\/bi501010q","article-title":"Polyglutamine amyloid core boundaries and flanking domain dynamics in huntingtin fragment fibrils determined by solid-state nuclear magnetic resonance","volume":"53","author":"Hoop","year":"2014","journal-title":"Biochemistry."},{"issue":"20","key":"10.1016\/bs.pmbts.2024.08.006_bib19","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1021\/jacs.8b02619","article-title":"Interaction of Huntingtin exon-1 peptides with lipid-based micellar nanoparticles probed by solution NMR and Q-band pulsed EPR","volume":"140","author":"Ceccon","year":"2018","journal-title":"J Am Chem Soc."},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.006_bib20","first-page":"475","article-title":"Small changes, big impact","volume":"17","author":"Ehrnhoefer","year":"2011","journal-title":"Neurosci."},{"issue":"50","key":"10.1016\/bs.pmbts.2024.08.006_bib21","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1705372114","article-title":"Phosphorylation of Huntingtin at residue T3 is decreased in huntington\u2019s disease and modulates mutant huntingtin protein conformation","volume":"114","author":"Cariulo","year":"2017","journal-title":"Proc Natl Acad Sci."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1021\/jacs.8b11441","article-title":"TiO2 nanoparticles catalyze oxidation of Huntingtin exon 1-derived peptides impeding aggregation: a quantitative NMR study of binding and kinetics","volume":"141","author":"Ceccon","year":"2019","journal-title":"J Am Chem Soc."},{"issue":"10","key":"10.1016\/bs.pmbts.2024.08.006_bib23","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1021\/acs.jctc.5b00208","article-title":"Molecular view of ligands specificity for CAG repeats in anti-Huntington therapy","volume":"11","author":"Bochicchio","year":"2015","journal-title":"J Chem Theory Comput."},{"issue":"17","key":"10.1016\/bs.pmbts.2024.08.006_bib24","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.1128\/MCB.00079-08","article-title":"Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation","volume":"28","author":"Shao","year":"2008","journal-title":"Mol Cell Biol."},{"issue":"9","key":"10.1016\/bs.pmbts.2024.08.006_bib25","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1073\/pnas.1821216116","article-title":"Probing initial transient oligomerization events facilitating huntingtin fibril nucleation at atomic resolution by relaxation-based NMR","volume":"116","author":"Kotler","year":"2019","journal-title":"Proc Natl Acad Sci."},{"issue":"4","key":"10.1016\/bs.pmbts.2024.08.006_bib26","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nsmb.1570","article-title":"Polyglutamine disruption of the Huntingtin Exon 1N terminus triggers a complex aggregation mechanism","volume":"16","author":"Thakur","year":"2009","journal-title":"Nat Struct Mol Biol."},{"issue":"4","key":"10.1016\/bs.pmbts.2024.08.006_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000772","article-title":"Polyglutamine induced misfolding of Huntingtin exon1 is modulated by the flanking sequences","volume":"6","author":"Lakhani","year":"2010","journal-title":"PLoS Comput Biol."},{"issue":"17","key":"10.1016\/bs.pmbts.2024.08.006_bib28","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1111\/j.1742-4658.2008.06561.x","article-title":"Huntington\u2019s disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases","volume":"275","author":"Truant","year":"2008","journal-title":"FEBS J."},{"issue":"50","key":"10.1016\/bs.pmbts.2024.08.006_bib29","doi-asserted-by":"crossref","first-page":"20075","DOI":"10.1073\/pnas.1320626110","article-title":"Unmasking the roles of N- and C-terminal flanking sequences from exon 1 of huntingtin as modulators of polyglutamine aggregation","volume":"110","author":"Crick","year":"2013","journal-title":"Proc Natl Acad Sci."},{"issue":"6","key":"10.1016\/bs.pmbts.2024.08.006_bib30","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1073\/pnas.1521933113","article-title":"Huntingtin exon 1 fibrils feature an interdigitated \u03b2-hairpin\u2013based polyglutamine core","volume":"113","author":"Hoop","year":"2016","journal-title":"Proc Natl Acad Sci."},{"issue":"7","key":"10.1016\/bs.pmbts.2024.08.006_bib31","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.jmb.2013.01.016","article-title":"\u03b2-hairpin-mediated nucleation of polyglutamine amyloid formation","volume":"425","author":"Kar","year":"2013","journal-title":"J Mol Biol."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/hmg\/ddl440","article-title":"The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis","volume":"16","author":"Rockabrand","year":"2007","journal-title":"Hum Mol Genet."},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.006_bib33","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jmb.2011.12.010","article-title":"Slow amyloid nucleation via \u03b1-helix-rich oligomeric intermediates in short polyglutamine-containing Huntingtin fragments","volume":"415","author":"Jayaraman","year":"2012","journal-title":"J Mol Biol."},{"issue":"19","key":"10.1016\/bs.pmbts.2024.08.006_bib34","doi-asserted-by":"crossref","first-page":"14777","DOI":"10.1074\/jbc.M109.093708","article-title":"Mutant Huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo","volume":"285","author":"Legleiter","year":"2010","journal-title":"J Biol Chem."},{"issue":"24","key":"10.1016\/bs.pmbts.2024.08.006_bib35","doi-asserted-by":"crossref","first-page":"15993","DOI":"10.1021\/acs.jmedchem.2c00799","article-title":"The emerging landscape of small-molecule therapeutics for the treatment of Huntington\u2019s disease","volume":"65","author":"Ahamad","year":"2022","journal-title":"J Med Chem."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib36","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol Rev."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib37","series-title":"Pathology, Prevention and Therapeutics of Neurodegenerative Disease","first-page":"117","article-title":"Clinical symptomatology of Huntington\u2019s disease","author":"Roth","year":"2019"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib38","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1038\/s41467-020-16318-1","article-title":"Truncation of mutant huntingtin in knock-in mice demonstrates exon1 huntingtin is a key pathogenic form","volume":"11","author":"Yang","year":"2020","journal-title":"Nat Commun."},{"issue":"7","key":"10.1016\/bs.pmbts.2024.08.006_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102062","article-title":"Protein interaction networks in neurodegenerative diseases: from physiological function to aggregation","volume":"298","author":"Calabrese","year":"2022","journal-title":"J Biol Chem."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.817013","article-title":"Striatal chloride dysregulation and impaired gabaergic signaling due to cation-chloride cotransporter dysfunction in Huntington\u2019s disease","volume":"15","author":"Serranilla","year":"2022","journal-title":"Front Cell Neurosci."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1212\/WNL.28.1.23","article-title":"Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies","volume":"28","author":"Goebel","year":"1978","journal-title":"Neurology."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-3-319-71779-1_3","article-title":"Mitochondrial dysfunction in Huntington\u2019s disease","volume":"1049","author":"Carmo","year":"2018","journal-title":"Adv Exp Med Biol."},{"issue":"20","key":"10.1016\/bs.pmbts.2024.08.006_bib43","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1093\/hmg\/ddq306","article-title":"Mitochondrial loss, dysfunction and altered dynamics in Huntington\u2019s disease","volume":"19","author":"Kim","year":"2010","journal-title":"Hum Mol Genet."},{"issue":"14","key":"10.1016\/bs.pmbts.2024.08.006_bib44","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/hmg\/ddh162","article-title":"Mutant Huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release","volume":"13","author":"Choo","year":"2004","journal-title":"Hum Mol Genet."},{"issue":"14","key":"10.1016\/bs.pmbts.2024.08.006_bib45","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.2174\/1389450122666210224105945","article-title":"Mitochondrial dysfunction in Huntington\u2019s disease: pathogenesis and therapeutic opportunities","volume":"22","author":"Sharma","year":"2021","journal-title":"Curr Drug Targets."},{"issue":"6","key":"10.1016\/bs.pmbts.2024.08.006_bib46","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s11064-023-03868-1","article-title":"An overview of the pathophysiological mechanisms of 3-nitropropionic acid (3-NPA) as a neurotoxin in a huntington\u2019s disease model and its relevance to drug discovery and development","volume":"48","author":"Upadhayay","year":"2023","journal-title":"Neurochem Res."},{"issue":"9","key":"10.1016\/bs.pmbts.2024.08.006_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223014","article-title":"Mitochondrial fragmentation and network architecture in degenerative diseases","volume":"14","author":"Shah","year":"2019","journal-title":"PLoS One."},{"issue":"4","key":"10.1016\/bs.pmbts.2024.08.006_bib48","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3109\/19401736.2013.878902","article-title":"Usage of mitochondrial D-loop variation to predict risk for Huntington disease","volume":"26","author":"Mousavizadeh","year":"2015","journal-title":"Mitochondrial DNA."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/JHD-160205","article-title":"Oxidative stress and Huntington\u2019s disease: the good, the bad, and the ugly","volume":"5","author":"Kumar","year":"2016","journal-title":"J Huntingt Dis."},{"issue":"11","key":"10.1016\/bs.pmbts.2024.08.006_bib50","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/jnr.24492","article-title":"Towards a comprehensive understanding of the contributions of mitochondrial dysfunction and oxidative stress in the pathogenesis and pathophysiology of Huntington\u2019s disease","volume":"97","author":"Tobore","year":"2019","journal-title":"J Neurosci Res."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib51","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1471-2199-9-84","article-title":"Mutant Huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington\u2019s disease","volume":"9","author":"Van Roon-Mom","year":"2008","journal-title":"BMC Mol Biol."},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.006_bib52","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.bbadis.2011.11.014","article-title":"Antioxidants in Huntington\u2019s disease","volume":"1822","author":"Johri","year":"2012","journal-title":"Biochim Biophys Acta\u2014Mol Basis Dis."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib53","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s13311-013-0180-y","article-title":"Monitoring autophagy in the treatment of protein aggregate diseases: steps toward identifying autophagic biomarkers","volume":"10","author":"Weihl","year":"2013","journal-title":"Neurotherapeutics."},{"issue":"6","key":"10.1016\/bs.pmbts.2024.08.006_bib54","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.celrep.2018.07.017","article-title":"Huntingtin aggregation impairs autophagy, leading to argonaute-2 accumulation and global MicroRNA dysregulation","volume":"24","author":"Pircs","year":"2018","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib55","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1471-4159.2005.03119.x","article-title":"Treatment with extracellular HSP70\/HSC70 protein can reduce polyglutamine toxicity and aggregation","volume":"94","author":"Novoselova","year":"2005","journal-title":"J Neurochem."},{"issue":"11","key":"10.1016\/bs.pmbts.2024.08.006_bib56","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1007\/s12035-021-02532-5","article-title":"Glyceraldehyde-3-phosphate dehydrogenase facilitates macroautophagic degradation of mutant huntingtin protein aggregates","volume":"58","author":"Chaudhary","year":"2021","journal-title":"Mol Neurobiol."},{"issue":"349","key":"10.1016\/bs.pmbts.2024.08.006_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2005633","article-title":"Huntingtin promotes MTORC1 signaling in the pathogenesis of Huntington\u2019s disease","volume":"7","author":"Pryor","year":"2014","journal-title":"Sci Signal."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib58","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.neuron.2014.09.034","article-title":"The neurology of MTOR","volume":"84","author":"Lipton","year":"2014","journal-title":"Neuron."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4161\/auto.5201","article-title":"A stress sensitive ER membrane-association domain in huntingtin protein defines a potential role for huntingtin in the regulation of autophagy","volume":"4","author":"Atwal","year":"2008","journal-title":"Autophagy."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/hmg\/ddr445","article-title":"IRE1 plays an essential role in ER stress-mediated aggregation of mutant Huntingtin via the inhibition of autophagy flux","volume":"21","author":"Lee","year":"2012","journal-title":"Hum Mol Genet."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000838","article-title":"Deletion of the Huntingtin polyglutamine stretch enhances neuronal autophagy and longevity in mice","volume":"6","author":"Zheng","year":"2010","journal-title":"PLoS Genet."},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.006_bib62","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nn.2528","article-title":"Cargo recognition failure is responsible for inefficient autophagy in Huntington\u2019s disease","volume":"13","author":"Martinez-Vicente","year":"2010","journal-title":"Nat Neurosci."},{"issue":"7","key":"10.1016\/bs.pmbts.2024.08.006_bib63","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.drudis.2014.02.014","article-title":"The many faces of autophagy dysfunction in Huntington\u2019s disease: from mechanism to therapy","volume":"19","author":"Cortes","year":"2014","journal-title":"Drug Discov Today."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib64","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1097-2765(04)00151-0","article-title":"Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins","volume":"14","author":"Venkatraman","year":"2004","journal-title":"Mol Cell."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib65","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nbd.2010.11.018","article-title":"Proteasomal dysfunction in aging and Huntington disease","volume":"43","author":"Li","year":"2011","journal-title":"Neurobiol Dis."},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.006_bib66","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/aps.2018.11","article-title":"Proteostasis in Huntington\u2019s disease: disease mechanisms and therapeutic opportunities","volume":"39","author":"Harding","year":"2018","journal-title":"Acta Pharmacol Sin."},{"issue":"8","key":"10.1016\/bs.pmbts.2024.08.006_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e07808","article-title":"Effects of excitotoxicity in the hypothalamus in transgenic mouse models of Huntington disease","volume":"7","author":"Henningsen","year":"2021","journal-title":"Heliyon."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib68","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s13311-012-0112-2","article-title":"Huntington\u2019s disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease","volume":"9","author":"Ehrlich","year":"2012","journal-title":"Neurotherapeutics."},{"issue":"4","key":"10.1016\/bs.pmbts.2024.08.006_bib69","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/j.1471-4159.1977.tb10641.x","article-title":"Loss of striatal serotonin synaptic receptor binding induced by kainic acid lesions: correlations with huntington\u2019s disease 1","volume":"28","author":"Schwarcz","year":"1977","journal-title":"J Neurochem."},{"issue":"6","key":"10.1016\/bs.pmbts.2024.08.006_bib70","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11515-016-1425-z","article-title":"Neuroprotective strategies for NMDAR-mediated excitotoxicity in Huntington\u2019s disease","volume":"11","author":"Girling","year":"2016","journal-title":"Front Biol (Beijing)."},{"issue":"7","key":"10.1016\/bs.pmbts.2024.08.006_bib71","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/0166-2236(90)90111-M","article-title":"Excitotoxic injury of the neostriatum: a model for Huntington\u2019s disease","volume":"13","author":"DiFiglia","year":"1990","journal-title":"Trends Neurosci."},{"issue":"11","key":"10.1016\/bs.pmbts.2024.08.006_bib72","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1093\/hmg\/ddv080","article-title":"HD IPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity","volume":"24","author":"Mattis","year":"2015","journal-title":"Hum Mol Genet."},{"issue":"10","key":"10.1016\/bs.pmbts.2024.08.006_bib73","article-title":"The role of glutamate in neuronal ion homeostasis: a case study of spreading depolarization","volume":"13","author":"H\u00fcbel","year":"2017","journal-title":"PLOS Comput\u00a0Biol."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib74","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40035-021-00278-7","article-title":"Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration","volume":"11","author":"Verma","year":"2022","journal-title":"Transl Neurodegener."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib75","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1602\/neurorx.1.1.101","article-title":"Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults","volume":"1","author":"Lipton","year":"2004","journal-title":"NeuroRX."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib76","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2010.01.008","article-title":"Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington\u2019s disease mice","volume":"65","author":"Milnerwood","year":"2010","journal-title":"Neuron."},{"issue":"35","key":"10.1016\/bs.pmbts.2024.08.006_bib77","doi-asserted-by":"crossref","first-page":"10928","DOI":"10.1523\/JNEUROSCI.2491-09.2009","article-title":"Interaction of postsynaptic density protein-95 with nmda receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington\u2019s disease","volume":"29","author":"Fan","year":"2009","journal-title":"J Neurosci."},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.006_bib78","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1046\/j.1471-4159.2001.00493.x","article-title":"Specific proteolysis of the NR2 subunit at multiple sites by calpain","volume":"78","author":"Guttmann","year":"2001","journal-title":"J Neurochem."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib79","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1124\/jpet.102.036962","article-title":"Proteolysis of the N-methyl-d-aspartate receptor by calpain in situ","volume":"302","author":"Guttmann","year":"2002","journal-title":"J Pharmacol Exp Ther."},{"issue":"12","key":"10.1016\/bs.pmbts.2024.08.006_bib80","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1523\/JNEUROSCI.22-12-04842.2002","article-title":"Calpain activation in Huntington\u2019s disease","volume":"22","author":"Gafni","year":"2002","journal-title":"J Neurosci."},{"issue":"48","key":"10.1016\/bs.pmbts.2024.08.006_bib81","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1523\/JNEUROSCI.4619-08.2008","article-title":"Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity","volume":"28","author":"Cowan","year":"2008","journal-title":"J Neurosci."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib82","doi-asserted-by":"crossref","DOI":"10.1002\/jnr.24495","article-title":"Dysfunctional striatal dopamine signaling in Huntington\u2019s disease","author":"Koch","year":"2019","journal-title":"J Neurosci Res."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.136289","article-title":"Reduced expression of dopamine D2 receptors on astrocytes in R6\/1 HD mice and HD post-mortem tissue","volume":"767","author":"Harris","year":"2022","journal-title":"Neurosci Lett."},{"issue":"6","key":"10.1016\/bs.pmbts.2024.08.006_bib84","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.neuron.2019.12.026","article-title":"Dopamine-evoked synaptic regulation in the nucleus accumbens requires astrocyte activity","volume":"105","author":"Corkrum","year":"2020","journal-title":"Neuron."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib85","first-page":"20","article-title":"Synaptic dysfunction in Huntington\u2019s disease: lessons from genetic animal models","volume":"28","author":"Cepeda","year":"2022","journal-title":"Neurosci."},{"issue":"17","key":"10.1016\/bs.pmbts.2024.08.006_bib86","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/hmg\/9.17.2539","article-title":"Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington\u2019s disease?","volume":"9","author":"Kennedy","year":"2000","journal-title":"Hum Mol Genet."},{"issue":"9","key":"10.1016\/bs.pmbts.2024.08.006_bib87","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1523\/JNEUROSCI.22-09-03404.2002","article-title":"Selective coupling of T-Type calcium channels to SK potassium channels prevents intrinsic bursting in dopaminergic midbrain neurons","volume":"22","author":"Wolfart","year":"2002","journal-title":"J Neurosci."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib88","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000375126","article-title":"Dysfunctional dopaminergic neurones in mouse models of huntington\u2019s disease: a role for SK3 channels","volume":"15","author":"Dall\u00e9rac","year":"2015","journal-title":"Neurodegener Dis."},{"issue":"34","key":"10.1016\/bs.pmbts.2024.08.006_bib89","doi-asserted-by":"crossref","first-page":"12218","DOI":"10.1073\/pnas.0502698102","article-title":"Unraveling a role for dopamine in huntington\u2019s disease: the dual role of reactive oxygen species and D2 receptor stimulation","volume":"102","author":"Charvin","year":"2005","journal-title":"Proc Natl Acad Sci."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib90","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.neuint.2016.11.003","article-title":"Dopamine exacerbates mutant huntingtin toxicity via oxidative-mediated inhibition of autophagy in SH-SY5Y neuroblastoma cells: beneficial effects of anti-oxidant therapeutics","volume":"101","author":"Vidoni","year":"2016","journal-title":"Neurochem Int."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2017.00193","article-title":"Microglial activation in the pathogenesis of Huntington\u2019s disease","volume":"9","author":"Yang","year":"2017","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2019.00258","article-title":"The role of microglia and astrocytes in Huntington\u2019s disease","volume":"12","author":"Palpagama","year":"2019","journal-title":"Front Mol Neurosci."},{"issue":"4","key":"10.1016\/bs.pmbts.2024.08.006_bib93","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nn.3668","article-title":"Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors","volume":"17","author":"Crotti","year":"2014","journal-title":"Nat Neurosci."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib94","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/glia.23050","article-title":"Frequency of nuclear mutant huntingtin inclusion formation in neurons and glia is cell-type-specific","volume":"65","author":"Jansen","year":"2017","journal-title":"Glia."},{"issue":"6","key":"10.1016\/bs.pmbts.2024.08.006_bib95","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.it.2015.04.007","article-title":"The choreography of neuroinflammation in Huntington\u2019s disease","volume":"36","author":"Crotti","year":"2015","journal-title":"Trends Immunol."},{"issue":"12","key":"10.1016\/bs.pmbts.2024.08.006_bib96","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3390\/ph7121028","article-title":"Role of microglial M1\/M2 polarization in relapse and remission of psychiatric disorders and diseases","volume":"7","author":"Nakagawa","year":"2014","journal-title":"Pharmaceuticals."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/541259","article-title":"The role of the immune system in Huntington\u2019s disease","volume":"2013","author":"Ellrichmann","year":"2013","journal-title":"Clin Dev Immunol."},{"issue":"4","key":"10.1016\/bs.pmbts.2024.08.006_bib98","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jnc.14723","article-title":"Alterations in synaptic function and plasticity in Huntington disease","volume":"150","author":"Smith\u2010Dijak","year":"2019","journal-title":"J Neurochem."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib99","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bbadis.2011.10.016","article-title":"Mutant Huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington\u2019s disease","volume":"1822","author":"Reddy","year":"2012","journal-title":"Biochim Biophys Acta\u2014Mol Basis Dis."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib100","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12017-018-8518-6","article-title":"The emerging roles of ferroptosis in Huntington\u2019s disease","volume":"21","author":"Mi","year":"2019","journal-title":"NeuroMolecular Med."},{"issue":"7","key":"10.1016\/bs.pmbts.2024.08.006_bib101","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1093\/hmg\/ddr024","article-title":"Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington\u2019s disease: implications for selective neuronal damage","volume":"20","author":"Shirendeb","year":"2011","journal-title":"Hum Mol Genet."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib102","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/hmg\/ddr475","article-title":"Mutant Huntingtin\u2019s interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington\u2019s disease","volume":"21","author":"Shirendeb","year":"2012","journal-title":"Hum Mol Genet."},{"issue":"39","key":"10.1016\/bs.pmbts.2024.08.006_bib103","doi-asserted-by":"crossref","first-page":"33719","DOI":"10.1074\/jbc.M111.236521","article-title":"Impaired \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor trafficking and function by mutant Huntingtin","volume":"286","author":"Mandal","year":"2011","journal-title":"J Biol Chem."},{"issue":"21","key":"10.1016\/bs.pmbts.2024.08.006_bib104","doi-asserted-by":"crossref","first-page":"8473","DOI":"10.1523\/JNEUROSCI.21-21-08473.2001","article-title":"Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington\u2019s disease mice","volume":"21","author":"Li","year":"2001","journal-title":"J Neurosci."},{"issue":"7","key":"10.1016\/bs.pmbts.2024.08.006_bib105","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nn.2346","article-title":"Pathogenic Huntingtin inhibits fast axonal transport by activating jnk3 and phosphorylating kinesin","volume":"12","author":"Morfini","year":"2009","journal-title":"Nat Neurosci."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib106","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.molmed.2004.12.002","article-title":"Polyglutamine expansion diseases: failing to deliver","volume":"11","author":"Morfini","year":"2005","journal-title":"Trends Mol Med."},{"issue":"45","key":"10.1016\/bs.pmbts.2024.08.006_bib107","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1206506109","article-title":"Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6\/2 mice","volume":"109","author":"Garriga-Canut","year":"2012","journal-title":"Proc Natl Acad Sci."},{"issue":"4","key":"10.1016\/bs.pmbts.2024.08.006_bib108","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3727\/096368916X690863","article-title":"Allele-specific reduction of the mutant Huntingtin allele using transcription activator-like effectors in human Huntington\u2019s disease fibroblasts","volume":"25","author":"Fink","year":"2016","journal-title":"Cell Transpl."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib109","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1007\/s12035-022-03150-5","article-title":"CRISPR\/Cas9 mediated therapeutic approach in Huntington\u2019s disease","volume":"60","author":"Alkanli","year":"2023","journal-title":"Mol Neurobiol."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40259-022-00519-9","article-title":"Antisense oligonucleotide therapy: from design to the Huntington disease clinic","volume":"36","author":"Rook","year":"2022","journal-title":"BioDrugs."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib111","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40035-017-0101-9","article-title":"RNAi mechanisms in Huntington\u2019s disease therapy: SiRNA versus ShRNA","volume":"6","author":"Aguiar","year":"2017","journal-title":"Transl Neurodegener."},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.006_bib112","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/hum.2013.200","article-title":"Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington\u2019s disease","volume":"25","author":"Stanek","year":"2014","journal-title":"Hum Gene Ther."},{"issue":"12","key":"10.1016\/bs.pmbts.2024.08.006_bib113","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the huntington disease gene\/allele-specific silencing of mutant Huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol Ther."},{"issue":"15","key":"10.1016\/bs.pmbts.2024.08.006_bib114","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1073\/pnas.0801775105","article-title":"Artificial MiRNAs mitigate ShRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi","volume":"105","author":"McBride","year":"2008","journal-title":"Proc Natl Acad Sci."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib115","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1749-6632.2009.04975.x","article-title":"Allele-selective inhibition of mutant Huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA","volume":"1175","author":"Hu","year":"2009","journal-title":"Ann N Y Acad Sci."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib116","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/brainsci10010043","article-title":"Therapeutic advances for Huntington\u2019s disease","volume":"10","author":"Kumar","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib117","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00337","article-title":"Immunotherapies in Huntington\u2019s disease and \u03b1-synucleinopathies","volume":"11","author":"Fatoba","year":"2020","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib118","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct Target Ther."},{"issue":"4","key":"10.1016\/bs.pmbts.2024.08.006_bib119","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nat Rev Drug Discov."},{"issue":"23","key":"10.1016\/bs.pmbts.2024.08.006_bib120","doi-asserted-by":"crossref","first-page":"15513","DOI":"10.1021\/acs.jmedchem.2c01290","article-title":"Recent update on the development of PCSK9 inhibitors for hypercholesterolemia treatment","volume":"65","author":"Ahamad","year":"2022","journal-title":"J Med Chem."},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.006_bib121","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.drudis.2022.01.014","article-title":"Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia","volume":"27","author":"Ahamad","year":"2022","journal-title":"Drug Discov Today."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112862","article-title":"Primed for global coronavirus pandemic: emerging research and clinical outcome","volume":"209","author":"Ahamad","year":"2021","journal-title":"Eur J Med Chem."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib123","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1021\/acschemneuro.0c00824","article-title":"Protective effect of natural products against Huntington\u2019s disease: an overview of scientific evidence and understanding their mechanism of action","volume":"12","author":"Lum","year":"2021","journal-title":"ACS Chem Neurosci."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib124","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3233\/JHD-229002","article-title":"Huntington\u2019s disease clinical trials corner: April 2022","volume":"11","author":"Estevez-Fraga","year":"2022","journal-title":"J Huntingt Dis."},{"issue":"7","key":"10.1016\/bs.pmbts.2024.08.006_bib125","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.drudis.2022.04.003","article-title":"Repurposing small-molecule drugs for modulating toxic protein aggregates in neurodegenerative diseases","volume":"27","author":"Liu","year":"2022","journal-title":"Drug Discov Today."},{"issue":"7","key":"10.1016\/bs.pmbts.2024.08.006_bib126","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","article-title":"Potential disease-modifying therapies for Huntington\u2019s disease: lessons learned and future opportunities","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib127","doi-asserted-by":"crossref","DOI":"10.1177\/11795735221092517","article-title":"Current and possible future therapeutic options for Huntington\u2019s disease","volume":"14","author":"Ferguson","year":"2022","journal-title":"J Cent Nerv Syst Dis."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib128","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/15476286.2022.2066334","article-title":"Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases","volume":"19","author":"Holm","year":"2022","journal-title":"RNA Biol."},{"issue":"4","key":"10.1016\/bs.pmbts.2024.08.006_bib129","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2174\/1389200223666220321103942","article-title":"A review on huntington protein: insight into protein aggregation and therapeutic interventions","volume":"23","author":"Srinivasan","year":"2022","journal-title":"Curr Drug Metab."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib130","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14728214.2021.1962285","article-title":"Emerging therapeutics in Huntington\u2019s disease","volume":"26","author":"Wiggins","year":"2021","journal-title":"Expert Opin Emerg Drugs."},{"issue":"16","key":"10.1016\/bs.pmbts.2024.08.006_bib131","doi-asserted-by":"crossref","first-page":"8363","DOI":"10.3390\/ijms22168363","article-title":"New avenues for the treatment of Huntington\u2019s disease","volume":"22","author":"Kim","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"January","key":"10.1016\/bs.pmbts.2024.08.006_bib132","article-title":"Recent developments in the management of Huntington\u2019s disease","volume":"120","author":"Devadiga","year":"2022","journal-title":"Bioorg Chem."},{"issue":"4","key":"10.1016\/bs.pmbts.2024.08.006_bib133","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2174\/1570159X21666230216104621","article-title":"The emerging landscape of natural small-molecule therapeutics for Huntington\u2019s disease","volume":"21","author":"Bhat","year":"2023","journal-title":"Curr Neuropharmacol."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.01.014","article-title":"Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia","author":"Ahamad","year":"2022","journal-title":"Drug Discov Today."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib135","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1021\/acschemneuro.0c00824","article-title":"Protective effect of natural products against Huntington\u2019s disease: an overview of scientific evidence and understanding their mechanism of action","volume":"12","author":"Lum","year":"2021","journal-title":"ACS Chem Neurosci."},{"issue":"10","key":"10.1016\/bs.pmbts.2024.08.006_bib136","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","article-title":"Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities","volume":"16","author":"Tabrizi","year":"2020","journal-title":"Nat Rev Neurol."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib137","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41588-019-0575-8","article-title":"A slipped-CAG DNA-binding small molecule induces trinucleotide-repeat contractions in vivo","volume":"52","author":"Nakamori","year":"2020","journal-title":"Nat Genet."},{"issue":"Suppl. 4","key":"10.1016\/bs.pmbts.2024.08.006_bib138","doi-asserted-by":"crossref","first-page":"16400","DOI":"10.1073\/pnas.182426599","article-title":"Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington\u2019s disease by using an automated filter retardation assay","volume":"99","author":"Heiser","year":"2002","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib139","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nm985","article-title":"Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease","volume":"10","author":"Tanaka","year":"2004","journal-title":"Nat Med."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib140","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1039\/C2MD20112G","article-title":"Preparation and evaluation of BBB-permeable trehalose derivatives as potential therapeutic agents for Huntington\u2019s Disease","volume":"4","author":"Im","year":"2013","journal-title":"Medchemcomm."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib141","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.nbd.2009.06.011","article-title":"Y-27632 improves rotarod performance and reduces huntingtin levels in R6\/2 mice","volume":"36","author":"Li","year":"2009","journal-title":"Neurobiol Dis."},{"issue":"4","key":"10.1016\/bs.pmbts.2024.08.006_bib142","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0896-6273(03)00697-4","article-title":"A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor","volume":"40","author":"Pollitt","year":"2003","journal-title":"Neuron."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib143","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nchembio852","article-title":"Selective inhibitors of death in mutant Huntingtin cells","volume":"3","author":"Varma","year":"2007","journal-title":"Nat Chem Biol."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib144","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1087057107299428","article-title":"Discovery of a novel small-molecule targeting selective clearance of mutant Huntingtin fragments","volume":"12","author":"Coufal","year":"2007","journal-title":"J Biomol Screen."},{"issue":"10","key":"10.1016\/bs.pmbts.2024.08.006_bib145","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1021\/ml400251g","article-title":"Fused 3-hydroxy-3-trifluoromethylpyrazoles inhibit mutant huntingtin toxicity","volume":"4","author":"La Rosa","year":"2013","journal-title":"ACS Med Chem Lett."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib146","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2174\/138620708783877753","article-title":"High throughput screening for neurodegeneration and complex disease phenotypes","volume":"11","author":"Varma","year":"2008","journal-title":"Comb Chem High Throughput Screen."},{"issue":"9","key":"10.1016\/bs.pmbts.2024.08.006_bib147","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1021\/acschemneuro.9b00167","article-title":"Discovery of arginine ethyl ester as polyglutamine aggregation inhibitor: conformational transitioning of Huntingtin N-terminus augments aggregation suppression","volume":"10","author":"Singh","year":"2019","journal-title":"ACS Chem Neurosci."},{"issue":"7781","key":"10.1016\/bs.pmbts.2024.08.006_bib148","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-019-1722-1","article-title":"Allele-selective lowering of mutant HTT protein by HTT\u2013LC3 linker compounds","volume":"575","author":"Li","year":"2019","journal-title":"Nature."},{"issue":"10","key":"10.1016\/bs.pmbts.2024.08.006_bib149","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/s41401-020-00605-0","article-title":"Gossypol, a novel modulator of VCP, induces autophagic degradation of mutant Huntingtin by promoting the formation of VCP\/P97-LC3-MHTT complex","volume":"42","author":"Li","year":"2021","journal-title":"Acta Pharmacol Sin."},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.006_bib150","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1021\/acsmedchemlett.0c00018","article-title":"Synthesis and selective functionalization of thiadiazine 1,1-dioxides with efficacy in a model of Huntington\u2019s disease","volume":"11","author":"Terrab","year":"2020","journal-title":"ACS Med Chem Lett."},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.006_bib151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cddis.2013.170","article-title":"Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-\u039aB pathway","volume":"4","author":"Hyrskyluoto","year":"2013","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib152","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1021\/acsmedchemlett.0c00532","article-title":"Evaluation of 5-(trifluoromethyl)-1,2,4-oxadiazole-based class iia HDAC inhibitors for Huntington\u2019s disease","volume":"12","author":"Stott","year":"2021","journal-title":"ACS Med Chem Lett."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib153","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bmcl.2018.11.009","article-title":"Development and characterization of a CNS-Penetrant benzhydryl hydroxamic acid class iia histone deacetylase inhibitor","volume":"29","author":"Luckhurst","year":"2019","journal-title":"Bioorganic Med Chem Lett."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib154","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1021\/acsmedchemlett.5b00302","article-title":"Potent, selective, and cns-penetrant tetrasubstituted cyclopropane class iia histone deacetylase (HDAC) inhibitors","volume":"7","author":"Luckhurst","year":"2016","journal-title":"ACS Med Chem Lett."},{"issue":"24","key":"10.1016\/bs.pmbts.2024.08.006_bib155","doi-asserted-by":"crossref","first-page":"9934","DOI":"10.1021\/jm4011884","article-title":"Design, synthesis, and biological evaluation of potent and selective class iia histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington\u2019s disease","volume":"56","author":"B\u00fcrli","year":"2013","journal-title":"J Med Chem."},{"issue":"7","key":"10.1016\/bs.pmbts.2024.08.006_bib156","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1021\/acschemneuro.0c00024","article-title":"Discovery and optimization of chromone derivatives as novel selective phosphodiesterase 10 inhibitors","volume":"11","author":"Yu","year":"2020","journal-title":"ACS Chem Neurosci."},{"issue":"29","key":"10.1016\/bs.pmbts.2024.08.006_bib157","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1038\/sj.onc.1204506","article-title":"Functional characterization and role of INrf2 in antioxidant response element-mediated expression and antioxidant induction of NAD(P)H:Quinone oxidoreductase1 gene","volume":"20","author":"Dhakshinamoorthy","year":"2001","journal-title":"Oncogene."},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.006_bib158","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1021\/acsmedchemlett.9b00594","article-title":"Combined peptide and small-molecule approach toward nonacidic Thiq inhibitors of the KEAP1\/NRF2 interaction","volume":"11","author":"Ontoria","year":"2020","journal-title":"ACS Med Chem\u00a0Lett."},{"issue":"6","key":"10.1016\/bs.pmbts.2024.08.006_bib159","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1021\/jm5000529","article-title":"Discovery of potent Keap1\u2013Nrf2 protein\u2013protein interaction inhibitor based on molecular binding determinants analysis","volume":"57","author":"Jiang","year":"2014","journal-title":"J Med Chem."},{"issue":"11","key":"10.1016\/bs.pmbts.2024.08.006_bib160","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1021\/acschemneuro.7b00283","article-title":"The medicinal chemistry of natural and semisynthetic compounds against Parkinson\u2019s and Huntington\u2019s diseases","volume":"8","author":"Zanforlin","year":"2017","journal-title":"ACS Chem Neurosci."},{"issue":"4","key":"10.1016\/bs.pmbts.2024.08.006_bib161","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3109\/01480545.2013.776583","article-title":"Protective effect of calendula officinalis linn. flowers against 3-nitropropionic acid induced experimental Huntington\u2019s disease in rats","volume":"36","author":"Shivasharan","year":"2013","journal-title":"Drug Chem Toxicol."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib162","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1080\/13880209.2017.1285945","article-title":"Ameliorating effect of celastrus paniculatus standardized extract and its fractions on 3-nitropropionic acid induced neuronal damage in rats: possible antioxidant mechanism","volume":"55","author":"Malik","year":"2017","journal-title":"Pharm Biol."},{"issue":"6","key":"10.1016\/bs.pmbts.2024.08.006_bib163","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ptr.3042","article-title":"Prophylaxis with centella asiatica confers protection to prepubertal mice against 3-nitropropionic-acid-induced oxidative stress in brain","volume":"24","author":"Shinomol","year":"2010","journal-title":"Phyther Res."},{"issue":"10","key":"10.1016\/bs.pmbts.2024.08.006_bib164","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3109\/13880209.2014.984856","article-title":"Protective effect of convolvulus pluricaulis standardized extract and its fractions against 3-nitropropionic acid-induced neurotoxicity in rats","volume":"53","author":"Malik","year":"2015","journal-title":"Pharm Biol."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib165","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1179\/1476830515Y.0000000022","article-title":"Neuroprotective potential of antioxidant potent fractions from convolvulus pluricaulis chois. in 3-nitropropionic acid challenged rats","volume":"19","author":"Kaur","year":"2016","journal-title":"Nutr Neurosci."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib166","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/723431","article-title":"Protective effects of aqueous extract of luehea divaricata against behavioral and oxidative changes induced by 3-nitropropionic acid in rats","volume":"2015","author":"Courtes","year":"2015","journal-title":"Evidence-Based Complement Altern Med."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib167","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1089\/jmf.2008.0028","article-title":"Possible neuroprotective effect of withania somnifera root extract against 3-nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of Huntington\u2019s disease","volume":"12","author":"Kumar","year":"2009","journal-title":"J Med Food."},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.006_bib168","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ana.20450","article-title":"Protective effects of ginseng components in a rodent model of neurodegeneration","volume":"57","author":"Lian","year":"2005","journal-title":"Ann Neurol."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib169","first-page":"1","article-title":"Korean red ginseng extract attenuates 3-nitropropionic acid-induced Huntington\u2019s-like symptoms","volume":"2013","author":"Jang","year":"2013","journal-title":"Evid-Based Complement Altern Med."},{"issue":"6","key":"10.1016\/bs.pmbts.2024.08.006_bib170","first-page":"61","article-title":"Neuroprotective effect of Zingiber officinale in 3-Np-induced Huntington disease","volume":"2","author":"Sharma","year":"2012","journal-title":"IOSR J Pharm."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib171","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1212\/WNL.0000000000003478","article-title":"A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease","volume":"88","author":"McGarry","year":"2017","journal-title":"Neurology."},{"issue":"18","key":"10.1016\/bs.pmbts.2024.08.006_bib172","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1093\/hmg\/ddl210","article-title":"Green tea (\u2212)-epigallocatechin-gallate modulates early events in Huntingtin misfolding and reduces toxicity in Huntington\u2019s disease models","volume":"15","author":"Ehrnhoefer","year":"2006","journal-title":"Hum Mol Genet."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib173","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2011.08.014","article-title":"Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington\u2019s disease and other neurodegenerative disorders","volume":"232","author":"Pasinetti","year":"2011","journal-title":"Exp Neurol."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib174","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.expneurol.2010.05.006","article-title":"Resveratrol protects against peripheral deficits in a mouse model of Huntington\u2019s disease","volume":"225","author":"Ho","year":"2010","journal-title":"Exp Neurol."},{"issue":"6","key":"10.1016\/bs.pmbts.2024.08.006_bib175","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.2174\/1871527313666140806160400","article-title":"The role of melatonin in multiple sclerosis, Huntington\u2019s disease and cerebral ischemia","volume":"13","author":"Escribano","year":"2014","journal-title":"CNS Neurol Disord - Drug Targets."},{"issue":"6","key":"10.1016\/bs.pmbts.2024.08.006_bib176","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.27010","article-title":"A Randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington\u2019s disease","volume":"32","author":"Verny","year":"2017","journal-title":"Mov Disord."},{"issue":"7","key":"10.1016\/bs.pmbts.2024.08.006_bib177","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134142","article-title":"Therapeutic effect of berberine on Huntington\u2019s disease transgenic mouse model","volume":"10","author":"Jiang","year":"2015","journal-title":"PLoS One."},{"issue":"53","key":"10.1016\/bs.pmbts.2024.08.006_bib178","doi-asserted-by":"crossref","first-page":"56053","DOI":"10.1074\/jbc.M409267200","article-title":"Celastrols as inducers of the heat shock response and cytoprotection","volume":"279","author":"Westerheide","year":"2004","journal-title":"J Biol Chem."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib179","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12031-016-0801-0","article-title":"Dihydromyricetin ameliorates 3NP-induced behavioral deficits and striatal injury in rats","volume":"60","author":"Mu","year":"2016","journal-title":"J Mol Neurosci."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib180","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.biopha.2016.11.111","article-title":"Effect of praeruptorin C on 3-nitropropionic acid induced Huntington\u2019s disease-like symptoms in mice","volume":"86","author":"Wang","year":"2017","journal-title":"Biomed Pharmacother."},{"issue":"06","key":"10.1016\/bs.pmbts.2024.08.006_bib181","doi-asserted-by":"crossref","DOI":"10.4172\/2161-1459.1000195","article-title":"The anti-depressant effect of praeruptorin C on the chronic unpredictable mild stress mouse modely","volume":"05","author":"Yang","year":"2015","journal-title":"Clin Exp Pharmacol."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib182","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.biopha.2015.11.009","article-title":"Effect of embelin against 3-nitropropionic acid-induced Huntington\u2019s disease in rats","volume":"77","author":"Dhadde","year":"2016","journal-title":"Biomed Pharmacother."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib183","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejphar.2004.09.061","article-title":"Effect of nicotine on 3-nitropropionic acid-induced oxidative stress in synaptosomes","volume":"504","author":"T\u00fanez","year":"2004","journal-title":"Eur J Pharmacol."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib184","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117223","article-title":"Genistein improves 3-NPA-induced memory impairment in ovariectomized rats: impact of its antioxidant, anti-inflammatory and acetylcholinesterase modulatory properties","volume":"10","author":"Menze","year":"2015","journal-title":"PLoS One."},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.006_bib185","article-title":"Protective activity of esculetin against 3-nitropropionic acid induced neurotoxicity via scavenging reactive oxygen species in male wistar rats","volume":"9","author":"Karandikar","year":"2017","journal-title":"Int J Pharmacogn Phytochem Res."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib186","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4103\/1673-5374.200812","article-title":"Adenyl cyclase activator forskolin protects against Huntington\u2019s disease-like neurodegenerative disorders","volume":"12","author":"Mehan","year":"2017","journal-title":"Neural Regen Res."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib187","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.3390\/molecules20033496","article-title":"Neferine attenuates the protein level and toxicity of mutant Huntingtin in PC-12 cells via induction of autophagy","volume":"20","author":"Wong","year":"2015","journal-title":"Molecules."},{"issue":"11","key":"10.1016\/bs.pmbts.2024.08.006_bib188","doi-asserted-by":"crossref","first-page":"22618","DOI":"10.3390\/ijms141122618","article-title":"Onjisaponin B Derived from Radix Polygalae Enhances Autophagy and Accelerates the Degradation of Mutant \u03b1-Synuclein and Huntingtin in PC-12 Cells","volume":"14","author":"Wu","year":"2013","journal-title":"Int J Mol Sci."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib189","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bbi.2019.03.001","article-title":"Gintonin, a ginseng-derived ingredient, as a novel therapeutic strategy for Huntington\u2019s disease: activation of the Nrf2 pathway through lysophosphatidic acid receptors","volume":"80","author":"Jang","year":"2019","journal-title":"Brain Behav Immun."},{"issue":"8","key":"10.1016\/bs.pmbts.2024.08.006_bib190","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/jnr.22017","article-title":"Ginsenosides protect striatal neurons in a cellular model of Huntington\u2019s disease","volume":"87","author":"Wu","year":"2009","journal-title":"J Neurosci Res."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib191","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/aps.2014.107","article-title":"Protopanaxtriol protects against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington\u2019s disease","volume":"36","author":"Gao","year":"2015","journal-title":"Acta Pharmacol Sin."},{"issue":"1\u20132","key":"10.1016\/bs.pmbts.2024.08.006_bib192","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11010-015-2525-9","article-title":"Neuroprotective efficacy of naringin on 3-nitropropionic acid-induced mitochondrial dysfunction through the modulation of nrf2 signaling pathway in PC12 cells","volume":"409","author":"Kulasekaran","year":"2015","journal-title":"Mol Cell Biochem."},{"issue":"7","key":"10.1016\/bs.pmbts.2024.08.006_bib193","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.neuint.2011.08.022","article-title":"Neuroprotective effect of naringin, a dietary flavonoid against 3-nitropropionic acid-induced neuronal apoptosis","volume":"59","author":"Gopinath","year":"2011","journal-title":"Neurochem Int."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib194","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1139\/cjpp-2015-0035","article-title":"Protective effect of naringin on 3-nitropropionic acid-induced neurodegeneration through the modulation of matrix metalloproteinases and glial fibrillary acidic protein","volume":"94","author":"Gopinath","year":"2016","journal-title":"Can J Physiol Pharmacol."},{"issue":"6","key":"10.1016\/bs.pmbts.2024.08.006_bib195","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4103\/ijp.IJP_11_18","article-title":"Neuroprotective effect of solanesol against 3-nitropropionic acid-induced Huntington\u2019s disease-like behavioral, biochemical, and cellular alterations: restoration of coenzyme-Q10-mediated mitochondrial dysfunction","volume":"50","author":"Mehan","year":"2018","journal-title":"Indian J Pharmacol."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib196","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.physbeh.2015.12.015","article-title":"Spermidine ameliorates 3-nitropropionic acid (3-NP)-induced striatal toxicity: possible role of oxidative stress, neuroinflammation, and neurotransmitters","volume":"155","author":"Jamwal","year":"2016","journal-title":"Physiol Behav."},{"issue":"4","key":"10.1016\/bs.pmbts.2024.08.006_bib197","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1007\/s12035-015-9230-2","article-title":"Sulforaphane ameliorates 3-nitropropionic acid-induced striatal toxicity by activating the Keap1-Nrf2-ARE pathway and inhibiting the MAPKs and NF-\u039aB pathways","volume":"53","author":"Jang","year":"2016","journal-title":"Mol Neurobiol."},{"key":"10.1016\/bs.pmbts.2024.08.006_bib198","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.biopha.2018.06.079","article-title":"Neuroprotective activity of tetramethylpyrazine against 3-nitropropionic acid induced Huntington\u2019s disease-like symptoms in rats","volume":"105","author":"Danduga","year":"2018","journal-title":"Biomed Pharmacother."},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.006_bib199","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.etp.2008.11.002","article-title":"ROS scavenging capacity and neuroprotective effect of \u03b1-mangostin against 3-nitropropionic acid in cerebellar granule neurons","volume":"61","author":"Pedraza-Chaverr\u00ed","year":"2009","journal-title":"Exp Toxicol Pathol."},{"issue":"9","key":"10.1016\/bs.pmbts.2024.08.006_bib200","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3109\/00207454.2013.872642","article-title":"Neuroprotective activity of L-theanine on 3-nitropropionic acid-induced neurotoxicity in rat striatum","volume":"124","author":"Thangarajan","year":"2014","journal-title":"Int J Neurosci."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib201","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/cns.12189","article-title":"Quercetin improves behavioral deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington\u2019s disease","volume":"20","author":"Chakraborty","year":"2014","journal-title":"CNS Neurosci Ther."},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.006_bib202","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/10286020902862194","article-title":"Sesamol attenuate 3-nitropropionic acid-induced huntington-like behavioral, biochemical, and cellular alterations in rats","volume":"11","author":"Kumar","year":"2009","journal-title":"J Asian Nat Prod Res."},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.006_bib203","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00702-009-0299-5","article-title":"Antioxidant Strategy to rescue synaptosomes from oxidative damage and energy failure in neurotoxic models in rats: protective role of S-allylcysteine","volume":"117","author":"Elinos-Calder\u00f3n","year":"2010","journal-title":"J Neural Transm."},{"issue":"29","key":"10.1016\/bs.pmbts.2024.08.006_bib204","doi-asserted-by":"crossref","first-page":"24460","DOI":"10.1074\/jbc.M112.382226","article-title":"Trans-(\u2212)-\u03b5-viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated protein kinase (AMPK), and protects cells in models of huntington disease","volume":"287","author":"Fu","year":"2012","journal-title":"J Biol Chem."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.006_bib205","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1139\/cjpp-2013-0398","article-title":"The anti-apoptotic and anti-inflammatory properties of puerarin attenuate 3-nitropropionic-acid induced neurotoxicity in rats","volume":"92","author":"Mahdy","year":"2014","journal-title":"Can J Physiol Pharmacol."},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.006_bib206","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1039\/C9FO02131K","article-title":"Ellagic acid rescues motor and cognitive deficits in the R6\/2 mouse model of Huntington\u2019s disease by lowering mutant Huntingtin protein","volume":"11","author":"Sun","year":"2020","journal-title":"Food Funct."},{"issue":"10","key":"10.1016\/bs.pmbts.2024.08.006_bib207","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1089\/jmf.2012.2698","article-title":"Neuroprotective effect of lutein against 3-nitropropionic acid\u2013induced Huntington\u2019s disease\u2013like symptoms: possible behavioral, biochemical, and cellular alterations","volume":"16","author":"Binawade","year":"2013","journal-title":"J Med Food."},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.006_bib208","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.neuint.2010.07.005","article-title":"Lycopene prevents 3-nitropropionic acid-induced mitochondrial oxidative stress and dysfunctions in nervous system","volume":"57","author":"Sandhir","year":"2010","journal-title":"Neurochem Int."},{"issue":"6","key":"10.1016\/bs.pmbts.2024.08.006_bib209","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020934","article-title":"A new drug design targeting the adenosinergic system for Huntington\u2019s disease","volume":"6","author":"Huang","year":"2011","journal-title":"PLoS One."}],"container-title":["Progress in Molecular Biology and Translational Science","Osmolytes and Intrinsically Disordered Proteins: From Functional Regulation to Disease Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117324001753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117324001753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T21:51:32Z","timestamp":1750888292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117324001753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443293207"],"references-count":209,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2024.08.006","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}